homepage-top-section

DRG is engaged in offering high-value data, analytics and insights products and services to the healthcare industry. The deal includes $900m in cash, as well as issuing of

Based in Menlo Park of California, Dermira is involved in the development of novel therapies to treat patients with chronic skin conditions. As per terms of the deal,

Under an exclusive worldwide research collaboration and licence agreement, the companies will be engaged in the development of small molecule inhibitors against several drug targets, which include the

Dysport, an injectable form of a botulinum neurotoxin type A product, is a substance derived from Clostridium bacteria producing botulinum toxin type A (BoNT-A), which blocks the effective

Kadcyla will be used to treat the patients who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. Kadcyla

The status has been provided to DCR-A1AT based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). A1AT deficiency

Under the deal, Amneal will acquire a 65.1% stake in AvKARE and its related affiliate conducting business as R&S Northeast. AvKARE is a private label provider of generic

ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases. The company’s clinical-stage pipeline consists of four drug

SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the SENS-111 was